Citations

Showing 10 of 108119 citations.

Functional deficiency in endogenous interleukin‐1 receptor antagonist in patients with febrile infection‐related epilepsy syndrome
Clarkson, Benjamin D. , LaFrance‐Corey, Reghann G., Kahoud, Robert J., Farias‐Moeller, Raquel , Payne, Eric T. , Howe, Charles L. , Clarkson, Benjamin D S , Howe, Charles L

Mayo Clinic

Annals of Neurology | February 19, 2019 | Volume: 85 | Issue: 4 | Pages: 526-537

10.1002/ana.25439 | PMID 30779222 Get It

ObjectiveWe recently reported successful treatment of a child with febrile infection‐related epilepsy syndrome (FIRES), a subtype of new onset refractory status epilepticus, with the recombinant interleukin‐1 (IL1) receptor antagonist (IL1RA) anakinra. On this basis, we tested whether endogenous IL1RA production or function is deficient in FIRES patients.MethodsLevels of IL1β and IL1RA were measured in serum and cerebrospinal fluid (CSF). The inhibitory activity of endogenous IL1RA was assessed using a cell‐based reporter assay. IL1RN gene variants were identified by sequencing. Expression levels for the secreted and intracellular isoforms of IL1RA were measured in patient and control cells by real‐time polymerase chain reaction.ResultsLevels of endogenous IL1RA and IL1β were elevated in the serum and CSF of patients with FIRES (n = 7) relative to healthy controls (n = 10). Serum from FIRES patients drove IL1R signaling activity and potentiated IL1R signaling in response to exogenous IL1β in a cell‐based reporter assay. Functional assessment of endogenous IL1RA activity in 3 FIRES patients revealed attenuated inhibition of IL1R signaling. Sequencing of IL1RN in our index patient revealed multiple variants. This was accompanied by reduced expression of intracellular but not secreted isoforms of IL1RA in the patient's peripheral blood mononuclear cells.InterpretationOur findings suggest that FIRES is associated with reduced expression of intracellular IL1RA isoforms and a functional deficiency in IL1RA inhibitory activity. These observations may provide insight into disease pathogenesis for FIRES and other inflammatory seizure disorders and may provide a valuable biomarker for therapeutic decision‐making. Ann Neurol 2019;85:526–537
Microencapsulated Immunoassays for Detection of Cytokines in Human Blood
Rahimian, Ali , Siltanen, Christian , Feyzizarnagh, Hamid , Escalante, Patricio , Revzin, Alexander

Mayo Clinic

ACS Sensors | February 18, 2019 | Volume: 4 | Issue: 3 | Pages: 578-585

10.1021/acssensors.8b01033 | PMID 30776214 Get It

MCAM abnormal expression and clinical outcome associations are highly cancer dependent as revealed through pan-cancer analysis
An, Yunxia, Wei, Nan , Cheng, Xiangsong, Li, Ying , Liu, Haiyang , Xu, Zhiwei , Zhang, Xiaoju , Sun, Zhifu

Mayo Clinic

Briefings in Bioinformatics | February 18, 2019 | Volume: 21 | Issue: 2 | Pages: 709-718

10.1093/bib/bbz019 | PMID 30815677 Get It

Abstract MCAM (CD146) is a cell surface adhesion molecule that has been reported to promote cancer development, progression and metastasis and is considered as a potential tumor biomarker and therapeutic target. However, inconsistent reports exist, and its clinical value is yet to be confirmed. Here we took advantage of several large genomic data collections (Genotype-Tissue Expression, The Cancer Genome Atlas and Cancer Cell Line Encyclopedia) and comprehensively analyzed MCAM expression in thousands of normal and cancer samples and cell lines along with their clinical phenotypes and drug response information. Our results show that MCAM is very highly expressed in large vessel tissues while majority of tissues have low or minimal expression. Its expression is dramatically increased in a few tumors but significantly decreased in most other tumors relative to their pairing normal tissues. Increased MCAM expression is associated with a higher tumor stage and worse patient survival for some less common tumors but not for major ones. Higher MCAM expression in primary tumors may be complicated by tumor-associated or normal stromal blood vessels yet its significance may differ from the one from cancer cells. MCAM expression is weakly associated with the response to a few small molecular drugs and the association with targeted anti-BRAF agents suggests its involvement in that pathway which warrants further investigation.
A Phase II Study of Alisertib in Children with Recurrent/Refractory Solid Tumors or Leukemia: Children's Oncology Group Phase I and Pilot Consortium (ADVL0921)
Mossé, Yaël P. , Fox, Elizabeth , Hall, David , Safgren, Stephanie L. , Carol, Hernán, Lock, Richard B. , Houghton, Peter J. , Smith, Malcolm A. , Barkauskas, Donald A. , Krailo, Mark , Voss, Stephan D. , Blaney, Susan M. , Weigel, Brenda J. , Teachey, David T. , Teachey, David T , Reid, Joel M. , Smith, Malcolm A , Berg, Stacey L , Safgren, Stephanie L , Berg, Stacey L.

Mayo Clinic

Clinical Cancer Research | February 18, 2019 | Volume: 25 | Issue: 11 | Pages: 3229-3238

10.1158/1078-0432.ccr-18-2675 | PMID 30777875 Get It

Abstract Purpose: Aurora A kinase (AAK) plays an integral role in mitotic entry, DNA damage checkpoint recovery, and centrosome and spindle maturation. Alisertib (MLN8237) is a potent and selective AAK inhibitor. In pediatric preclinical models, antitumor activity was observed in neuroblastoma, acute lymphoblastic leukemia, and sarcoma xenografts. We conducted a phase 2 trial of alisertib in pediatric patients with refractory or recurrent solid tumors or acute leukemias (NCT01154816). Patients and Methods: Alisertib (80 mg/m2/dose) was administered orally, daily for 7 days every 21 days. Pharmacogenomic (PG) evaluation for polymorphisms in the AURK gene and drug metabolizing enzymes (UGT1A1*28), and plasma pharmacokinetic studies (PK) were performed. Using a 2-stage design, patients were enrolled to 12 disease strata (10 solid tumor and 2 acute leukemia). Response was assessed after cycle 1, then every other cycle. Results: A total of 139 children and adolescents (median age, 10 years) were enrolled, 137 were evaluable for response. Five objective responses were observed (2 complete responses and 3 partial responses). The most frequent toxicity was myelosuppression. The median alisertib trough concentration on day 4 was 1.3 μmol/L, exceeding the 1 μmol/L target trough concentration in 67% of patients. No correlations between PG or PK and toxicity were observed. Conclusions: Despite alisertib activity in pediatric xenograft models and cogent pharmacokinetic-pharmacodynamic relationships in preclinical models and adults, the objective response rate in children and adolescents receiving single-agent alisertib was less than 5%.
In vivo comparison of shape memory polymer foam‐coated and bare metal coils for aneurysm occlusion in the rabbit elastase model
Herting, Scott M. , Boyle, Anthony J., Nash, Landon D., Asnafi, Solmaz , Jakaitis, Daniel R. , Johnson, Collin R., Graul, Lance M. , Yeh, Chung, Kallmes, David F. , Kadirvel, Ramanathan , Maitland, Duncan J. , Ding, Yonghong , Dai, Daying , Yeh, Chung

Mayo Clinic

Journal of Biomedical Materials Research Part B: Applied Biomaterials | February 18, 2019 | Volume: 107 | Issue: 8 | Pages: 2466-2475

10.1002/jbm.b.34337 | PMID 30775843 Get It

AbstractShape memory polymer (SMP) foam‐coated coils (FCCs) are new embolic coils coated with porous SMP designed to expand for increased volume filling and enhanced healing after implantation. The purpose of this study was to compare chronic aneurysm healing after treatment with SMP FCCs to bare platinum coil (BPC) controls in the rabbit elastase aneurysm model. BPCs or SMP FCCs were implanted in rabbit elastase‐induced aneurysms for follow‐up at 30 days (n = 10), 90 days (n = 5), and 180 days (n = 12 for BPCs; n = 14 for SMP FCCs). Aneurysm occlusion and histologic healing, including a qualitative healing score, neointima thickness, collagen deposition, and inflammation were compared between the two groups. The mean neointima thickness was significantly greater in groups treated with SMP FCCs for all three time points. Histologic healing scores and collagen deposition quantification suggested that aneurysms treated with SMP FCCs experience more complete healing of the dome by 90 days, but the differences were not statistically significant. More progressive occlusion and recanalization were observed in aneurysms treated with SMP FCCs, but neither difference was statistically significant. Additionally, the SMP foam used in the FCCs was found to degrade faster in the rabbit elastase model than expected based on previous studies in a porcine sidewall aneurysm model. This study suggests that SMP FCCs can promote neointima formation along the aneurysm neck, and may lead to more complete healing of the dome and neck. These findings indicate potential benefits of this device for aneurysm occlusion procedures. © 2019 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater 107B:2466–2475, 2019.
Faculty Opinions recommendation of Neuraxial anesthesia in parturients with intracranial pathology: a comprehensive review and reassessment of risk.
Sviggum, Hans P.

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | February 18, 2019 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.724505806.793556165 Get It

PPAR-γ in Macrophages Limits Pulmonary Inflammation and Promotes Host Recovery following Respiratory Viral Infection
Huang, Su, Zhu, Bibo , Cheon, In Su , Goplen, Nick P., Jiang, Li , Zhang, Ruixuan, Mack, Matthias , Kaplan, Mark H. , Kaplan, Mark H , Peebles, R. Stokes , Limper, Andrew H. , Sun, Jie

Mayo Clinic

Journal of Virology | February 18, 2019 | Volume: 93 | Issue: 9 | Pages: No page available

10.1128/jvi.00030-19 | PMID 30787149 Get It

Respiratory viral infections, like IAV and respiratory syncytial virus (RSV) infections, impose great challenges to public health. Alveolar macrophages (AM) are lung-resident immune cells that play important roles in protecting the host against IAV and RSV infections. However, the underlying molecular mechanisms by which AM modulate host inflammation, disease development, and tissue recovery are not very well understood. Here we identify that PPAR-γ expression in AM is crucial to suppress pulmonary inflammation and diseases and to promote fast host recovery from IAV and RSV infections. Our data suggest that targeting macrophage PPAR-γ may be a promising therapeutic option in the future to suppress acute inflammation and simultaneously promote recovery from severe diseases associated with respiratory viral infections.
Controlling antimicrobial use and decreasing microbiological laboratory tests for urinary tract infections in spinal-cord-injury patients with chronic indwelling catheters
Shah, Palak S., Cannon, Joan P., Sullivan, Christine , Nemchausky, Bernard A., Pachucki, Constance T.

Mayo Clinic

American Journal of Health-System Pharmacy | February 18, 2019 | Volume: 62 | Issue: 1 | Pages: 74-77

10.1093/ajhp/62.1.74 | PMID 15658076 Get It

Computer program for handling investigational oncology drugs
Burnham, Nora, Elcombe, Sharon A., Skorlinski, Christopher R., Kosanke, Jon L., Kovach, John S.

Mayo Clinic

American Journal of Health-System Pharmacy | February 18, 2019 | Volume: 46 | Issue: 9 | Pages: 1821-1824

10.1093/ajhp/46.9.1821 Get It